ArticleJournal of clinical and experimental hematopathology : JCEH2022

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.

Kantaro Ishitsuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.